In a 3,100-word article, the Milwaukee Journal Sentinel reports that “a Milwaukee Journal Sentinel/MedPage Today analysis of 54 new cancer drugs found that over the last decade the FDA allowed 74% of them on the market without proof that they extended life.” Additionally, there was often no “proof of improved quality of life.” The FDA “instead…approved the drugs based on surrogate measures, such as a tumor shrinking, rather than the gold standard and most reliable measure of cancer research, patients actually surviving longer.” In an email, FDA spokeswoman Stephanie Yao said, “While it is acknowledged that shrinking a tumor or preventing it from progressing may not be a direct measure of improvement in survival, symptoms or function, as the magnitude of that shrinkage or delay in growth increases, our confidence that the result is likely to predict clinical benefit increases.”
In a 1,400-word article, the Milwaukee Journal Sentinel reports, “Critics say using surrogate measures to determine if a drug should be approved can backfire. Surrogates can mask complications that work against survival or quality of life, said Richard Deyo, a professor of evidence-based medicine at Oregon Health and Science University.”
The Milwaukee Journal Sentinel reports, “While the FDA says it prefers to see high response rates in the drugs it approves based on surrogate measures,” certain “low-response rate” medications “also get on the market.” This is due in part, “the agency says,” to “a lack of alternatives for people with life-threatening cancers.” The Milwaukee Journal Sentinel also profiles a patient with colon cancer who is has been taking Stivarga (regorafenib).
From the news release of the American Association for Justice.


